

Thomas J Blom

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3598523/publications.pdf>

Version: 2024-02-01

37
papers

623
citations

567281

15
h-index

610901

24
g-index

37
all docs

37
docs citations

37
times ranked

864
citing authors

#	ARTICLE	IF	CITATIONS
1	A preliminary study of the effects of mindfulness-based cognitive therapy on structural brain networks in mood-dysregulated youth with a familial risk for bipolar disorder. <i>Microbial Biotechnology</i> , 2022, 16, 1011-1019.	1.7	4
2	Pretreatment Alterations and Acute Medication Treatment Effects on Brain Task-Related Functional Connectivity in Youth With Bipolar Disorder: A Neuroimaging Randomized Clinical Trial. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2022, 61, 1023-1033.	0.5	6
3	Familial risk for bipolar I disorder is associated with erythrocyte omega-3 polyunsaturated fatty acid deficits in youth with attention-deficit hyperactivity disorder. <i>Psychiatry Research</i> , 2022, 313, 114587.	3.3	0
4	Quantification of diet quality utilizing the rapid eating assessment for participants-shortened version in bipolar disorder: Implications for prospective depression and cardiometabolic studies. <i>Journal of Affective Disorders</i> , 2022, 310, 150-155.	4.1	5
5	Symptom Profiles, But Not Prefrontal Neurochemistry, Differentiate ADHD Youth With and Without a Family History of Bipolar I Disorder. <i>Journal of Attention Disorders</i> , 2022, 26, 1762-1773.	2.6	3
6	N-acetylcysteine for depression and glutamate changes in the left prefrontal cortex in adolescents and young adults at risk for bipolar disorder: A pilot study. <i>Microbial Biotechnology</i> , 2021, , .	1.7	3
7	Network-level functional topological changes after mindfulness-based cognitive therapy in mood dysregulated adolescents at familial risk for bipolar disorder: a pilot study. <i>BMC Psychiatry</i> , 2021, 21, 213.	2.6	12
8	A Randomized, Double-Blind, Controlled Trial of Lithium Versus Quetiapine for the Treatment of Acute Mania in Youth with Early Course Bipolar Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2021, 31, 485-493.	1.3	16
9	Revisiting the bipolar disorder with migraine phenotype: Clinical features and comorbidity. <i>Journal of Affective Disorders</i> , 2021, 295, 156-162.	4.1	3
10	Study protocol and rationale for a randomized, placebo-controlled trial of solriamfetol to treat binge eating disorder. <i>Contemporary Clinical Trials</i> , 2021, 110, 106587.	1.8	1
11	Mindfulness-based cognitive therapy for children and adolescents with anxiety disorders at-risk for bipolar disorder: A psychoeducation waitlist controlled pilot trial. <i>Microbial Biotechnology</i> , 2020, 14, 211-219.	1.7	23
12	Evening chronotype as a discrete clinical subphenotype in bipolar disorder. <i>Journal of Affective Disorders</i> , 2020, 266, 556-562.	4.1	31
13	The Importance of Second-Generation Antipsychotic-Related Weight Gain and Adherence Barriers in Youth with Bipolar Disorders: Patient, Parent, and Provider Perspectives. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2020, 30, 376-380.	1.3	16
14	Effects of Fish Oil Monotherapy on Depression and Prefrontal Neurochemistry in Adolescents at High Risk for Bipolar I Disorder: A 12-Week Placebo-Controlled Proton Magnetic Resonance Spectroscopy Trial. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2020, 30, 293-305.	1.3	11
15	A Preliminary Study of the Effects of Treatment with Lithium Versus Quetiapine on Attention of Adolescents with Bipolar Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2020, 30, 465-469.	1.3	5
16	Capacity to provide informed consent among adults with bipolar disorder. <i>Journal of Affective Disorders</i> , 2019, 242, 1-4.	4.1	2
17	Neurophysiological effects of multiple mood episodes in bipolar disorder. <i>Bipolar Disorders</i> , 2019, 21, 503-513.	1.9	27
18	Longitudinal proton spectroscopy study of the prefrontal cortex in youth at risk for bipolar disorder before and after their first mood episode. <i>Bipolar Disorders</i> , 2019, 21, 330-341.	1.9	15

#	ARTICLE	IF	CITATIONS
19	Effect of lisdexamfetamine on emotional network brain dysfunction in binge eating disorder. <i>Psychiatry Research - Neuroimaging</i> , 2019, 286, 53-59.	1.8	24
20	Factor analysis of the eating disorder diagnostic scale in individuals with bipolar disorder. <i>Eating Behaviors</i> , 2019, 33, 30-33.	2.0	4
21	Placebo response and cessation in binge eating disorder: A pooled analysis of two randomized parallel-group clinical trials. <i>European Eating Disorders Review</i> , 2019, 27, 421-428.	4.1	3
22	Cardiometabolic risks and omega-3 index in recent-onset bipolar I disorder. <i>Bipolar Disorders</i> , 2018, 20, 658-665.	1.9	11
23	Sex differences in the ACTH and cortisol response to pharmacological probes are stressor-specific and occur regardless of alcohol dependence history. <i>Psychoneuroendocrinology</i> , 2018, 94, 72-82.	2.7	6
24	Combination Phentermine-Topiramate Extended Release for the Treatment of Binge Eating Disorder: An Open-Label, Prospective Study. <i>Innovations in Clinical Neuroscience</i> , 2018, 15, 17-21.	0.1	16
25	Prediction of lithium response in first-episode mania using the LITHium Intelligent Agent (<sc>LITHIA</sc>): Pilot data and proof-of-concept. <i>Bipolar Disorders</i> , 2017, 19, 259-272.	1.9	59
26	White matter volumes in youth offspring of bipolar parents. <i>Journal of Affective Disorders</i> , 2017, 209, 246-253.	4.1	22
27	Adolescents with or at ultra-high risk for bipolar disorder exhibit erythrocyte docosahexaenoic acid and eicosapentaenoic acid deficits: a candidate prodromal risk biomarker. <i>Microbial Biotechnology</i> , 2016, 10, 203-211.	1.7	42
28	fMRI brain activation changes following treatment of a first bipolar manic episode. <i>Bipolar Disorders</i> , 2016, 18, 490-501.	1.9	48
29	Lisdexamfetamine dimesylate in binge eating disorder: a placebo controlled trial. <i>Human Psychopharmacology</i> , 2016, 31, 382-391.	1.5	20
30	Clinical features of bipolar spectrum with binge eating behaviour. <i>Journal of Affective Disorders</i> , 2016, 201, 95-98.	4.1	29
31	Prevalence and correlates of DSM-5 eating disorders in patients with bipolar disorder. <i>Journal of Affective Disorders</i> , 2016, 191, 216-221.	4.1	62
32	Neurofunctional effects of quetiapine in patients with bipolar mania. <i>Bipolar Disorders</i> , 2015, 17, 444-449.	1.9	8
33	First-episode bipolar disorder is associated with erythrocyte membrane docosahexaenoic acid deficits: Dissociation from clinical response to lithium or quetiapine. <i>Psychiatry Research</i> , 2015, 230, 447-453.	3.3	22
34	A Randomized, Placebo-Controlled, Double-Blinded Trial of Duloxetine in the Treatment of General Fatigue in Patients With Chronic Fatigue Syndrome. <i>Psychosomatics</i> , 2015, 56, 242-253.	2.5	15
35	Placebo Cessation in Binge Eating Disorder: Effect on Anthropometric, Cardiovascular, and Metabolic Variables. <i>European Eating Disorders Review</i> , 2015, 23, 86-88.	4.1	6
36	Placebo Response in Binge Eating Disorder: A Pooled Analysis of 10 Clinical Trials from One Research Group. <i>European Eating Disorders Review</i> , 2014, 22, 140-146.	4.1	27

#	ARTICLE	IF	CITATIONS
37	Risk and Protective Factors Associated With Substance Use Disorders in Adolescents With First-Episode Mania. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2014, 53, 771-779.	0.5	16